首页> 外文OA文献 >Technology commercialization strategy in a dynamic context: Developing specialized complementary assets in entrepreneurial firms
【2h】

Technology commercialization strategy in a dynamic context: Developing specialized complementary assets in entrepreneurial firms

机译:动态背景下的技术商业化战略:在创业公司中开发专业的互补资产

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A firm that lacks the specialized complementary assets necessary to commercialize an innovation faces a trade-off between contracting with an incumbent to access those assets and integrating downstream into commercialization. According to the framework developed in the prior literature, under a strong appropriability regime the innovator is likely to be better off contracting with an incumbent (as long as it can negotiate reasonable terms). However, we argue that if the innovator can learn from its experience in product commercialization, and thereby build its own commercialization capabilities, then the benefits of integrating downstream may outweigh the opportunity costs of learning and foregone profits. Alternatively, by engaging in joint commercialization, the innovator may be able to avoid these opportunity costs, albeit at the expense of higher inter-organizational governance costs. We illustrate the relationship between the choice of commercialization mode, commercialization experience, and performance in the context of the pharmaceutical industry. Specifically, we study how commercialization mode and experience affects the likelihood of drug approval. We find that when innovators lacking commercialization experience participate in the commercialization process though either joint commercialization or by commercializing alone, the product is less likely to be approved. However, innovators that have participated in the commercialization process in the past are more likely to successfully commercialize subsequent innovations under joint commercialization than those which have only contracted the commercialization to an incumbent. The results suggest that in some circumstances participating in the commercialization process, either through self-commercialization or by engaging in joint commercialization, may be the optimal strategy even for firms without the requisite complementary assets.
机译:缺乏将创新商品化所需的专门补充资产的公司将面临与老牌公司签约以获取这些资产和将下游整合到商品化之间的权衡。根据现有文献中开发的框架,在强大的专有性制度下,创新者可能会更好地与老牌公司签约(只要它可以协商合理的条件)。但是,我们认为,如果创新者可以从其产品商业化的经验中吸取教训,从而建立自己的商业化能力,那么下游整合的好处可能会超过学习的机会成本和所放弃的利润。或者,通过参与联合商业化,创新者可以避免这些机会成本,尽管是以组织间较高的治理成本为代价的。我们说明了在制药行业中商业化模式选择,商业化经验和绩效之间的关系。具体来说,我们研究了商业化模式和经验如何影响药物批准的可能性。我们发现,当缺乏商业化经验的创新者通过联合商业化或通过单独商业化参与商业化过程时,产品被批准的可能性就较小。但是,与仅将商业化承包给现有企业的创新者相比,过去参与商业化过程的创新者更有可能在联合商业化下成功地将后续创新商业化。结果表明,在某些情况下,通过自我商业化或通过联合商业化参与商业化过程,即使对于没有必要补充资产的公司而言,也可能是最优策略。

著录项

  • 作者

    Hsu David H.; Wakeman Simon;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号